Celonic will manufacture over 100 million doses of Curevac's COVID-19 Vaccine Candidate, CVnCoV CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020 and CVnCoV is the vaccine candidate chosen for…..
Celonic to Boost its Cell & Gene Therapy Production with Facility in the Upcoming Life Science Park Rheintal in Stein Celonic, a leading global CDMO, specialized in development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, announced a long-term lease agreement for a new production site and office…..